Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311760 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06311760 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 32 participants.
The verdict
NCT06311760, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD0292 following intravenous (IV) administration of single ascending doses to healthy adult participants.
Interventions
- DRUG Placebo
- DRUG AZD0292
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2025-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06311760
The ClinicalTrials.gov registry entry for NCT06311760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06311760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06311760 about?
NCT06311760 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants". This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD0292 following intravenous (IV) administration of single ascending doses to healthy adult participants.
What is the current status of trial NCT06311760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-04-09. Estimated completion is 2025-02-20.
What interventions are being tested in trial NCT06311760?
The interventions under investigation include: Placebo (DRUG), AZD0292 (DRUG).
Who is sponsoring clinical trial NCT06311760?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.